litlas
Log inCreate account

Parameswaran Hari

Active 2005–2025

173
Papers
20,803
Citations
79
h-index
170
i10-index

Citations

Citations per year for Parameswaran Hari1990: 1 citations2003: 1 citations2005: 1 citations2006: 7 citations2007: 12 citations2008: 11 citations2009: 18 citations2010: 24 citations2011: 33 citations2012: 38 citations2013: 90 citations2014: 108 citations2015: 105 citations2016: 98 citations2017: 115 citations2018: 103 citations2019: 521 citations2020: 838 citations2021: 1,079 citations2022: 1,043 citations2023: 848 citations2024: 1,369 citations2025: 569 citations2026: 10 citations1991–2002: no citations, so these years are not shown2004: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,733 citing papers, 27.6% of this breakdownGermany: 657 citing papers, 6.6% of this breakdownChina: 641 citing papers, 6.5% of this breakdownItaly: 571 citing papers, 5.8% of this breakdownUnited Kingdom: 523 citing papers, 5.3% of this breakdownFrance: 503 citing papers, 5.1% of this breakdownSpain: 480 citing papers, 4.8% of this breakdownNetherlands: 353 citing papers, 3.6% of this breakdownCanada: 327 citing papers, 3.3% of this breakdownAustralia: 224 citing papers, 2.3% of this breakdownJapan: 216 citing papers, 2.2% of this breakdownSwitzerland: 211 citing papers, 2.1% of this breakdown
0%27.6%Other 24.8%

Institutions

Fields

  • Medicine86.9%
  • Biochemistry, Genetics and Molecular Biology8.9%
  • Immunology and Microbiology2.6%
  • Engineering0.2%
  • Pharmacology, Toxicology and Pharmaceutics0.2%
  • Neuroscience0.2%
  • Other1%

Topics

  • Multiple Myeloma Research and Treatments11.8%
  • CAR-T cell therapy research11.5%
  • Protein Degradation and Inhibitors5.8%
  • Hematopoietic Stem Cell Transplantation5%
  • Peptidase Inhibition and Analysis3.2%
  • Immune Cell Function and Interaction3.1%
  • Other59.6%

Coauthors

All papers

Open in search
  1. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

    Authors: Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, A. Keith Stewart, Parameswaran Hari, Myo Htut, Alexander M. Lesokhin, Abhinav Deol, Nikhil C. Munshi, Elizabeth O’Donnell, David Avigan, Indrajeet Singh, Enrique Zudaire, Tzu‐Min Yeh, Alicia J. Allred, Yunsi Olyslager, Arnob Banerjee, Carolyn C. Jackson, Jenna D Goldberg, Jordan M. Schecter, William Deraedt, Sen Hong Zhuang, Jeffrey R. Infante, Dong Geng, Xiaoling Wu, Marlene J. Carrasco-Alfonso, Muhammad Akram, Farah Hossain, Syed Rizvi, Frank Fan, Yi Lin, Thomas G. Martin, Sundar Jagannath - The Lancet 2021 cited by 1,664

  2. Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

    Authors: Thomas G. Martin, Saad Z. Usmani, Jesús G. Berdeja, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, David Avigan, Abhinav Deol, Myo Htut, Alexander M. Lesokhin, Nikhil C. Munshi, Elizabeth O’Donnell, A. Keith Stewart, Jordan M. Schecter, Jenna D. Goldberg, Carolyn C. Jackson, Tzu‐Min Yeh, Arnob Banerjee, Alicia J. Allred, Enrique Zudaire, William Deraedt, Yunsi Olyslager, Changwei Zhou, Lida Pacaud, Deepu Madduri, Andrzej Jakubowiak, Yi Lin, Sundar Jagannath - Journal of Clinical Oncology 2022 cited by 633

  3. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

    Authors: Jason Chesney, Karl D. Lewis, Harriet M. Kluger, Omid Hamid, Eric D. Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo‐Musibay, Giao Q. Phan, John M. Kirkwood, Jessica C. Hassel, Marlana Orloff, James Larkin, Jeffrey S. Weber, Andrew J.S. Furness, Nikhil I. Khushalani, Theresa Medina, Michael E. Egger, Friedrich Graf Finckenstein, Madan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod A. Sarnaik - Journal for ImmunoTherapy of Cancer 2022 cited by 320

  4. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

    Authors: Ujjawal H. Gandhi, Robert F. Cornell, Arjun Lakshman, Zhubin Gahvari, Elizabeth McGehee, Megan H. Jagosky, Ridhi Gupta, William Varnado, Mark A. Fiala, Saurabh Chhabra, Ehsan Malek, Joshua Mansour, Barry Paul, Alyssa Barnstead, Saranya Kodali, Amarendra Kumar Neppalli, Michaela Liedtke, Swapna Narayana, Kelly Godby, Yubin Kang, Ankit Kansagra, Elvira Umyarova, Emma C. Scott, Parameswaran Hari, Ravi Vij, Saad Z. Usmani, Natalie S. Callander, Shaji Kumar, Luciano J. Costa - Leukemia 2019 cited by 616

  5. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

    Authors: Nirav N. Shah, Bryon D. Johnson, Dina Schneider, Fenlu Zhu, Anikó Szabó, Carolyn A. Keever-Taylor, Winfried Krueger, Andrew Worden, Michael J. Kadan, Sharon Yim, Ashley M. Cunningham, Mehdi Hamadani, Timothy S. Fenske, Boro Dropulić, Rimas J. Orentas, Parameswaran Hari - Nature Medicine 2020 cited by 459

  6. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

    Authors: Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka, Ajai Chari, Al‐Ola Abdallah, Natalie S. Callander, Nikoletta Lendvai, Douglas W. Sborov, Attaya Suvannasankha, Katja Weisel, Lionel Karlin, Edward N. Libby, Bertrand Arnulf, Thierry Façon, Cyrille Hulin, K. Martin Kortüm, Paula Rodríguez‐Otero, Saad Z. Usmani, Parameswaran Hari, Rachid Baz, Hang Quach, Philippe Moreau, Peter M. Voorhees, Ira Gupta, Axel Hoos, Eric Zhi, January Baron, Trisha Piontek, Eric Lewis, Roxanne C. Jewell, Elisha J. Dettman, Rakesh Popat, Simona Degli Esposti, Joanna Opalinska, Paul G. Richardson, Adam D. Cohen - The Lancet Oncology 2019 cited by 796

  7. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

    Authors: Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai Dholaria, Timothy M. Schmidt, Kelly Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Smith Giri, Anita D’Souza, Aric C. Hall, Pamela Hardwick, James Omel, Robert F. Cornell, Parameswaran Hari, Natalie S. Callander - The Lancet Haematology 2023 cited by 150

  8. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

    Authors: Anita D’Souza, Caitrin Fretham, Stephanie J. Lee, Mukta Arora, Janet Brunner, Saurabh Chhabra, Steven M. Devine, Mary Eapen, Mehdi Hamadani, Parameswaran Hari, Marcelo C. Pasquini, Waleska S. Pérez, Rachel Phelan, Marcie Riches, J. Douglas Rizzo, Wael Saber, Bronwen E. Shaw, Stephen R. Spellman, Patricia Steinert, Daniel J. Weisdorf, Mary M. Horowitz - Biology of Blood and Marrow Transplantation 2020 cited by 711

  9. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group

    Authors: Noopur Raje, Elias Anaissie, Shaji Kumar, Sagar Lonial, Thomas G Martin, Morie A. Gertz, Amrita Krishnan, Parameswaran Hari, Heinz Ludwig, Elizabeth O’Donnell, Andrew J. Yee, Jonathan L. Kaufman, Adam D. Cohen, Laurent Garderet, Ashutosh F Wechalekar, Evangelos Terpos, Navin Khatry, Rubén Niesvizky, Qing Yi, Douglas Joshua, Tapan Saikia, Nelson Leung, Monika Engelhardt, Mohamad Mothy, Andrew R. Branagan, Ajai Chari, Tony Reiman, Brea Lipe, Joshua Richter, S. Vincent Rajkumar, Jesús F. San Miguel, Kenneth C. Anderson, Edward A. Stadtmauer, Rao Prabhala, Phillip McCarthy, Nikhil C. Munshi - The Lancet Haematology 2022 cited by 191

  10. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

    Authors: Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai Dholaria, Timothy M. Schmidt, Kelly Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Smith Giri, Anita D’Souza, Aric C. Hall, Pamela Hardwick, James Omel, Robert F. Cornell, Parameswaran Hari, Natalie S. Callander - Journal of Clinical Oncology 2021 cited by 255

  11. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    Authors: Philippe Moreau, Shaji Kumar, Jesús F. San Miguel, Faith E. Davies, Elena Zamagni, Nizar J. Bahlis, Heinz Ludwig, Joseph Mıkhael, Evangelos Terpos, Fredrik Schjesvold, Thomas G. Martin, Kwee Yong, Brian G.M. Durie, Thierry Façon, Artur Jurczyszyn, Surbhi Sidana, Noopur Raje, Niels W.C.J. van de Donk, Sagar Lonial, Michèle Cavo, Sigurður Y. Kristinsson, Suzanne Lentzsch, Roman Hájek, Kenneth C. Anderson, Cristina João, Hermann Einsele, Pieter Sonneveld, Monika Engelhardt, Rafaël Fonseca, Annette Juul Vangsted, Katja Weisel, Rachid Baz, Vânia Hungria, Jesús G. Berdeja, Fernando Leal da Costa, Ângelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloísa Riva, P. Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf‐Henrik Mellqvist, Dominik Dytfeld, Jean‐Luc Harousseau, Hartmut Goldschmidt, Jacob P. Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksaç, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah A. Holstein, Orhan Sezer, Simon J. Harrison, Hareth Nahi, Gordon Cook, María‐Victoria Mateos, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Paul G. Richardson - The Lancet Oncology 2021 cited by 268

  12. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

    Authors: María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, Albert Oriol, David Simpson, Anupkumar George, Hartmut Goldschmidt, Alessandra Larocca, Asher Chanan‐Khan, Daniel W. Sherbenou, Irit Avivi, Noam Benyamini, Shinsuke Iida, Morio Matsumoto, Kenshi Suzuki, Vincent Ribrag, Saad Z. Usmani, Sundar Jagannath, Enrique M. Ocio, Paula Rodríguez‐Otero, Jesús F. San Miguel, Uma Kher, Mohammed Z.H. Farooqui, Jason J. Z. Liao, Patricia Marinello, Sagar Lonial, Andrew J. Nicol, George Grigoriadis, John Catalano, Richard LeBlanc, Mohamed Elemary, Nizar J. Bahlis, Thierry Façon, Lionel Karlin, Vincent Ribrag, Michel Attal, Hartmut Goldschmidt, Monika Engelhardt, Katja Weisel, Andréas Mackensen, Arnon Nagler, Dina Ben Yehuda, Irit Avivi, Noam Benyamini, Hila Magen‐Nativ, Antonio Palumbo, Michèle Cavo, Kensei Tobinai, Shinsuke Iida, Takaai Chou, Kenshi Suzuki, Hiroshi Kosugi, Masafumi Taniwaki, Kazutaka Sunami, Morio Matsumoto, Kiyoshi Ando, Peter Ganly, Hilary Blacklock, David Simpson, Anupkumar George, Fredrik Schjesvold, Bjørn Tore Gjertsen, Juan José Lahuerta, Joan Bladé, Albert Oriol Rocafiguera, María‐Victoria Mateos, Paula Rodríguez‐Otero, Sarah M. Larson, Djordje Atanackovic, Srinivas Devarakonda, Jacob D. Bitran, Jeffrey A. Zonder, Neil Morganstein, Mohammad Hay, Asher Chanan‐Khan, Gene Saylors, Ebenezer A. Kio, Ira Oliff, Dean Kirkel, Mikhail Shtivelband, Carrie Yuen, Andrew J. Yee, Jatin J. Shah, Myo Htut, Shahzad Raza, Saurabh Chhabra, Patrick J. Stiff, Parameswaran Hari, Bruce Bank, Ehsan Malek, Cristina Gasparetto, Ycaoub Faroun, Daniel W. Sherbenou, William Kreisle, Seema Singhal, Jacalyn Rosenblatt, Saad Z. Usmani, Wes Lee, Hana Safah, Jose Lutzky and 21 more - The Lancet Haematology 2019 cited by 253

  13. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

    Authors: Javier Bolaños‐Meade, Ran Reshef, Raphael Fraser, Mingwei Fei, Sunil Abhyankar, Zaid Al‐Kadhimi, Amin M. Alousi, Joseph H. Antin, Sally Arai, Kate Bickett, Yi‐Bin Chen, Lloyd E. Damon, Yvonne A. Efebera, Nancy L. Geller, Sergio Giralt, Parameswaran Hari, Shernan G. Holtan, Mary M. Horowitz, David A. Jacobsohn, Richard J. Jones, Jane L. Liesveld, Brent R. Logan, Margaret L. MacMillan, Marco Mielcarek, Pierre Noël, Joseph Pidala, David Porter, Iskra Pusic, Ronald Sobecks, Scott R. Solomon, Daniel J. Weisdorf, Juan Wu, Marcelo C. Pasquini, John Koreth - The Lancet Haematology 2019 cited by 281

  14. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

    Authors: Philip L. McCarthy, Kouros Owzar, Craig C. Hofmeister, David D. Hurd, Hani Hassoun, Paul G. Richardson, Sergio Giralt, Edward A. Stadtmauer, Daniel J. Weisdorf, Ravi Vij, Jan S. Moreb, Natalie S. Callander, Koen van Besien, Teresa Gentile, Luis Isola, Richard T. Maziarz, Don A. Gabriel, Asad Bashey, Heather Landau, Thomas Martin, Muzaffar H. Qazilbash, Denise Levitan, Brian McClune, Robert Schlossman, Vera Hárs, John Postiglione, Chen Jiang, Elizabeth Bennett, Susan Barry, Linda R. Bressler, Michael E. Kelly, Michele Seiler, Cara A. Rosenbaum, Parameswaran Hari, Marcelo C. Pasquini, Mary M. Horowitz, Thomas C. Shea, Steven M. Devine, Kenneth C. Anderson, Charles Linker - New England Journal of Medicine 2012 cited by 1,143

  15. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study

    Authors: Roy F. Chemaly, Lynn El Haddad, Drew J. Winston, Scott D. Rowley, Kathleen M Mulane, Pranatharthi Chandrasekar, Robin K. Avery, Parameswaran Hari, Karl S. Peggs, Deepali Kumar, Rajneesh Nath, Per Ljungman, Sherif B. Mossad, Sanjeet Dadwal, Ted Blanchard, Dimpy P. Shah, Ying Jiang, Ella Ariza‐Heredia - Clinical Infectious Diseases 2020 cited by 110

  16. Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma

    Authors: Meera Mohan, Sneha Nagavally, Binod Dhakal, Sabarinath Venniyil Radhakrishnan, Saurabh Chhabra, Anita D’Souza, Parameswaran Hari - Blood Advances 2021 cited by 60

  17. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    Authors: Shaji Kumar, Meletios Α. Dimopoulos, Efstathios Kastritis, Evangelos Terpos, Hareth Nahi, Hartmut Goldschmidt, Jens Hillengaß, Xavier Leleu, Meral Beksaç, Melissa Alsina, Albert Oriol, Michèle Cavo, Enrique M. Ocio, María‐Victoria Mateos, Elizabeth O’Donnell, Ravi Vij, H M Lokhorst, Niels W.C.J. van de Donk, Chang‐Ki Min, Tomer M. Mark, Ingemar Turesson, Markus Hansson, Heinz Ludwig, Sundar Jagannath, Michel Delforge, Charalampia Kyriakou, Parameswaran Hari, Ulf‐Henrik Mellqvist, Saad Z. Usmani, Dominik Dytfeld, Ashraf Badros, Philippe Moreau, K Kim, P R Otero, J H Lee, Chaim Shustik, Daniel D. Waller, Wee Joo Chng, Shuji Ozaki, J-J Lee, Javier de la Rubia, Hyeon‐Seok Eom, Laura Rosiñol, Juan José Lahuerta, Anna Sureda, Jin Seok Kim, B G M Durie - Leukemia 2017 cited by 354

  18. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

    Authors: Dan T. Vogl, Noopur Raje, Sundar Jagannath, Paul G. Richardson, Parameswaran Hari, Robert Z. Orlowski, Jeffrey G. Supko, David Tamang, Min Yang, Simon S. Jones, Catherine Wheeler, Robert J Markelewicz, Sagar Lonial - Clinical Cancer Research 2017 cited by 251

  19. Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies

    Authors: Nirav N. Shah, Theresa Maatman, Parameswaran Hari, Bryon D. Johnson - Frontiers in Oncology 2019 cited by 173

  20. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

    Authors: Luciano J. Costa, Benjamin A. Derman, Susan Bal, Surbhi Sidana, Saurabh Chhabra, Rebecca Silbermann, Jing C. Ye, Gordon Cook, Robert F. Cornell, Sarah A. Holstein, Qian Shi, James Omel, Natalie S. Callander, Wee Joo Chng, Vânia Hungria, Ângelo Maiolino, Edward A. Stadtmauer, Sergio Giralt, Marcelo C. Pasquini, Andrzej Jakubowiak, Gareth J. Morgan, Amrita Krishnan, Graham Jackson, Mohamad Mohty, María‐Victoria Mateos, Meletious A. Dimopoulos, Thierry Façon, Andrew Spencer, Jesús F. San Miguel, Parameswaran Hari, Saad Z. Usmani, Salomon Manier, Phillip McCarthy, Shaji Kumar, Francesca Gay, Bruno Paiva - Leukemia 2020 cited by 119

  21. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center

    Authors: Fenlu Zhu, Nirav N. Shah, Huiqing Xu, Dina Schneider, Rimas J. Orentas, Boro Dropulić, Parameswaran Hari, Carolyn A. Keever-Taylor - Cytotherapy 2017 cited by 119

  22. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

    Authors: Edward A. Stadtmauer, Marcelo C. Pasquini, Beth Blackwell, Parameswaran Hari, Asad Bashey, Steven M. Devine, Yvonne A. Efebera, S. Ganguly, Cristina Gasparetto, Nancy L. Geller, Mary M. Horowitz, John Koreth, Kristin Knust, Heather Landau, Claudio G. Brunstein, Philip L. McCarthy, Courtney Nelson, Muzaffar H. Qazilbash, Nina Shah, David H. Vesole, Ravi Vij, Dan T. Vogl, Sergio Giralt, George Somlo, Amrita Krishnan - Journal of Clinical Oncology 2019 cited by 259

  23. A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

    Authors: Simon J. Harrison, Monique C. Minnema, Hans C. Lee, Andrew Spencer, Prashant Kapoor, Deepu Madduri, Jeremy T. Larsen, Sikander Ailawadhi, Jonathan L. Kaufman, Marc S. Raab, Parameswaran Hari, Shinsuke Iida, Ravi Vij, Faith E. Davies, Robin Lesley, Vijay Upreti, Zhao Yang, Anjali Sharma, Alex C. Minella, Suzanne Lentzsch - Blood 2020 cited by 112

  24. Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome

    Authors: Joanna Zurko, Bryon D. Johnson, Emilie Aschenbrenner, Timothy S. Fenske, Mehdi Hamadani, Parameswaran Hari, Nirav N. Shah - JAMA Oncology 2022 cited by 39